Sign in

CIK 0001840229

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

MiNK Therapeutics, Inc.

Sign in to watch
Ticker
INKT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 212-994-8250
Business address
149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, 10010
Former names
AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.
  1. 4 Grant or award Director acquired 21,802 shares (grant or award)
  2. 4 Grant or award Director acquired 15,454 shares (grant or award)
  3. 4 Grant or award Director acquired 17,841 shares (grant or award)
  4. 4 Grant or award Director acquired 15,077 shares (grant or award)
  5. 4 Grant or award Director acquired 17,967 shares (grant or award)
  6. 4 Grant or award Director acquired 16,185 shares (grant or award)
  7. 4 Grant or award Director acquired 18,685 shares (grant or award)
  8. 4 Grant or award Director acquired 15,790 shares (grant or award)
  9. 4 Grant or award Director acquired 18,816 shares (grant or award)
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Grant or award Director acquired 17,068 shares (grant or award)
  13. 4 Grant or award Director acquired 17,188 shares (grant or award)
  14. 4 Grant or award Director acquired 14,424 shares (grant or award)
  15. 4 Grant or award Director acquired 14,784 shares (grant or award)
  16. 4 Open-market buy 10% owner bought 22,975 shares at an average $1.10 ($25,270)
  17. 4 Other disposition Chief Executive Officer disposed of 695,750 shares (other)
  18. 4 Open-market buy 10% owner bought 15,001 shares at $1.09 ($16,380)
  19. 4 Shares withheld for taxes Chief Executive Officer gave up 148,550 shares (to pay taxes)
  20. 4 Exercise or conversion Chief Executive Officer acquired 695,750 shares (option exercise)

Page 4 of 8 · 145 filings